20250707-中邮证券-医药生物行业报告_PD-（L）1_VEGF双抗BD预期引发创新药行情持续热潮_20页_2mb

Summary of Securities Research Report: Pharmaceutical and Biological Industry Weekly

Overall Market Performance

The pharmaceutical and biological industry advanced 3.64% in the week, outperforming the CSI 300 index by 2.1 percentage points and ranking 4th among its 31 sub-sectors. Key drivers included strong performance in biologic products and innovation drugs, fueled by positive market sentiment and supportive policy developments. The industry benefited from a combination of policy support and financial inflows, positioning it for sustained growth in the short to medium term.

Key Developments: PD-(L)-1/VEGF Bispecific Antibody Deal

AstraZeneca's potential 150 billion USD deal with Summit Therapeutics (Covalence's partner) for the PD-1/VEGF bispecific antibody AK112 has significantly boosted the innovation drug sector. This deal underscores multinational corporations' confidence in the next-generation immuno-oncology potential of PD-1/VEGF bispecific antibodies, which offer synergistic benefits such as immune modulation and anti-angiogenesis. Products like Tecentriq JV by MSD and others in the pipeline are expected to generate substantial commercial value, driving ongoing deals in this space. This focus on bispecific antibodies continues to generate excitement and investment opportunities.

New Drug Approval: Fuxin Qibaiabode for Gout Treatment

Fuxin Qibaiabode, approved for treating acute gout attacks in patients unsuitable for conventional treatments, has marked a milestone in the field. The IL-1β-targeted drug addresses the growing need for novel therapies in gout management, which affects a large patient population. With China's antihyperuricemic drug market projected to reach over 100 billion RMB by 2030, this approval signals increased innovation and market opportunities.

Investment Recommendations

Strong recommendations include H-share innovation drugs (e.g., Constellion, SinoBiocor, Johnson & Johnson's partner), A-share firms (e.g., Zengjinyu, Yifang Bio), medical devices (e.g., Yimoxinag, Mindray Biomedical), and CROs (e.g., WuXi Apppt, AInnoVate). Key strategies involve focusing on out-of-China deals, clinical data strength, and policy-driven opportunities. Sectors like medical diagnostics and vaccines also show potential, with specific stocks suggested for investment based on their growth prospects and market positions.

Risk Factors

Notable risks include potential escalation of US-China trade tensions, intensifying industry competition, policy execution risks, and commercial product hurdles. Market volatility and unforeseen events could impact performance, emphasizing the need for cautious investment decisions.

Outlook

The industry outlook remains positive, with innovation and out-of-country deals likely sustaining growth. Policy shifts, such as those supporting premium generics and healthcare reforms, are expected to further bolster the sector over the medium term.